reason report
hold hors uncertainti garland init
bottom line commerci success soliri op
valid complement protein therapeut target address
human diseas consist reason honing-in
upstream protein may deliv superior therapeut
benefit vs and/or open new indic current agent
-- investig approv -- yet demonstr favor
safeti efficaci late-stag program paroxysm nocturn
hemoglobinuria pnh geograph atrophi ga mid-to-l stage
program glomerulopathi cold agglutinin diseas cad
cash could intrigu name
investor howev see sever reason balanc warrant
cautiou view posit outcom next catalyst
pegasu head-to-head pnh trial trial like baked-in current price
initi coverag mp rate pt
near-term pnh data like baked-in see tough
commerci outlook thereaft think current valuat reflect
posit readout pegasu pnh expect jan lead
indic pnh may becom first commerci oppti -- albeit
soliris-switch pt initi -- futur label expans possibl pend
princ result howev strong adopt soliri rapid
on-going convers pt ultomiri repres tough landscap
break view issu anemia reticulocytosi
transfusion-depend appear less sever pnh space today
accord medacorp kol check project ww peak sale
posit progress thu far cad sni nr pose cardin
issu potenti leverag hematolog sale forc cad
logic expans oppti view posit updat
plaudit studi includ improv hemoglobin
biomark encourag await strategi updat
earli similar pnh howev face anoth strong
competitor sutimlimab sni nr whose posit cardin
data could lead bla file potenti fda approv
sni like extens commerci footprint hematolog
space envis uphil battl second-to-mkt product like
nevertheless estim ww peak sale
ga approv uncertain market oppti combin
unmet need address market like render ga promin
growth driver support posit filli
data said cautiou view stem neg preced
lampalizumab rhhbi nr well medacorp kol check
blend revenu multipl
analysi dcf disc rate
net debt total capit
per share
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
question clinic implic treatment anti-vegf
set high bar among ophthalmologist -- efficaci safeti --
difficult fulli embrac profil consist dose-depend
increas onset exud continu declin visual acuiti
demand dose regimen monthli backdrop old pt
demograph consist kol cautiou outlook commerci
uptak project conserv peak penetr translat
gross sale ww
smaller competit market role complement
diseas nephropathi repres addit avenu
growth initi indic evalu discoveri
trial howev narrow scope despit posit
data thu far cogniz intensifi competit
achn mp op like necessit key differenti
howev subcutan sq rout administr vs oral
competitor may slow attempt play catch-up competitor
estim peak sale ww
futur expans opportun potenti valu remain
tbd believ earli inning complement-target
drug addit indic -- beyond discuss herein
-- may present futur expans opportun compani pend
announc progress howev cautiou
relianc unclear prospect follow-on candid like
cite initi indic also pose potenti
challeng look ahead given technolog compstatin analog
 in-licens one univers pennsylvania
also remain cautiou long-term revenu growth potenti
hold hors uncertainti garland init mp pt
market close
evalu cycliz peptid address complement-medi diseas
lead compound pegcetacoplan seek inhibit complement protein address diseas
paroxysm nocturn hemoglobinuria pnh geograph atrophi ga complement-medi nephropathi
strategi underli mechan evolut past attempt soliri ultomiri op
lampalizumab rhhbi nr
success outcom could demonstr superior target vs complement protein
despit theoret infect risk associ complement inhibit clinic real-world experi thu far
demonstr minim caus concern follow appropri vaccin
sight rare preval indic exemplifi ga program seek
address complic associ gene therapi whose unmet need remain unclear junctur
 asid ga face competit approv soon-to-b agent indic
 paroxysm nocturn hemoglobinuria pnh could tough market crack alxn op
soliri ultomiri standard care soc
 narrow market opportun initi intend aiha cold agglutinin disease/cad
loom competit sutimlimab sni nr
 despit phase filli outcom rhhbi nr chroma spectri remind
potenti risk ga clinic meaning also question incid exud
declin visual acuiti alreadi old demograph
 attract market aggreg narrow scope
potenti competit avacopan achn mp op
respect complement-medi nephropathi
 pend life cycl manag lcm strategi opportun via look
question may smaller anticip
deriv one-year pt base
blend dcf analysi revenu
multipl analysi broadli valuat includ
program evalu system intravitr
administr lead
indic assign probabl success po
paroxysm nocturn hemoglobinuria pnh
follow po cold agglutinin
diseas cad glomerulopathi
respect intravitr program geograph
atrophi ga ascrib po base posit
data thu far among program believ ga
afford largest oppti peak sale
smallest oppti pnh
late clinical-stag compani use
discount rate termin growth rate
npv net market cap per share valu discount rate/cost growth outstand mm revenu multipl blend pt apelli dcf cf investing- net borrowing- apelli inc
risk valuat
clinical-stag compani risk includ clinic regulatori financi
 overwhelm relianc outcom program pnh cad ga
guarante program succeed
 pnh first indic like receiv regulatori approv uphil battl strong
incumb soliri ultomiri op
 despit signific market opportun posit phase filli data ga biolog evid
appear riski medacorp kol cite concern trend exud clinic
meaning data visual acuiti
 unlik safeti ramif modul less understood full safeti profil includ
 clinic risk associ clinic candid
drugindicationev agglutinin diseas cad program/strategi updateearli nocturn hemoglobinuria pnh phase pegasu top-line dataearli nocturn hemoglobinuria pnh nda nocturn hemoglobinuria pnh submissionearli atrophi ga phase derbi oak enrol atrophi ga phase derbi oak top-line atrophi ga nda atrophi ga atrophi ga fda atrophi ga ema iv complement-respons aav gene therapyiniti phase sq apelli inc
expand therapeut applic complement-
current valuat heavili reliant pursuit
pnh competit achn-alxn combin could
complic competit dynam
may deliv greater therapeut benefit
increas familiar complement-target drug
among physician patient could facilit market
signific unmet need ga approv therapi
potenti better patient complianc adher
ga cad riskier program pnh
emerg threat weekli sq oral drug
subcutan sq stabl room temperatur
biosimilar mp
like steep opex compet establish
recent suggest interest complement space
player pursu larg market
rarx mp -ucb achn mp -alxn op
despit posit data challeng appeal ga
safety/toler inhibitor remain tbd
uncertain opportun
base incid paroxysm nocturn hemoglobinuria pnh estim
 paroxysm nocturn hemoglobinuria pnh patient ww profil thu far
believ primarili target patient us row respect
current treat specif estim treat patient sub-optimal
respond need better control anemia blood transfus
 peak penetr us row respect annual price
per year model gross sale ww ahead
pegasu data assign probabl success po ww market entri
believ strong incumb op may limit commerci uptak
 oral complement inhibitor addit competit danicopan progress may
pressur futur commerci prospect pnh
paroxysm nocturn hemoglobinuria pnh background
mutat phosphatidylinositol n-acetylglucosaminyltransferas
subunit piga gene acquir inherit
result destruct red blood cell rbc immun cell
intravascular hemolysi membran attack complex
extravascular hemolysi macrophag liver/spleen
mechan
altern lectin classic pathway converg
upstream target soliris/ultomiri op
standard
newli diagnos pnh evolv aplast anemia
ultomiri expect improv upon soliri
earli promis data phase paddock pharoah studi
phase pegasu head-to-head vs soliri data
soliri revolution pnh treatment paradigm solid soc
soliri re-shap pnh treatment despit cumbersom regimen induct mainten dose
 effect intravascular hemolysi indic ldh reduct
 primari endpoint hemoglobin stabil transfus avoid
long-term yr follow-up studi show develop human anti-human antibodi
haha soliri
extens physician experi sinc fda ema jun approv among other
soliri hemoglobin stabil transfus
ultomiri rais bar pnh therapi
even less frequent dose ultomiri achiev non-inferior soliri
 inhibit intravascular hemolysi indic ldh reduct normal
 improv transfus qol breakthrough hemolysi stabil hemoglobin also
support ultomiri efficaci
safeti profil also compar soliri headach account major
strong patient complianc also compar soliri
non-inferior achiev lb ub ci treatment differ meet pre-defin requir
adiffer proport patient bodd ratio cdiffer chang vs baselin
breakthrough hemolysi achiev stat sig endpoint test superior
long-term observ support strong profil ultomiri pnh
studi treatment-na pnh eculizumab-switch pnh
long-term ultomiri use show minim occurr breakthrough hemolysi bth
 e-r switcher show less bth r-r rate low overal week
 bth defin
new worsen sign symptom intravascular hemolysi
major advers vascular event includ thrombosi dysphagia erectil dysfunct
presenc elev ldh level uln prior reduct ldh uln
wk bth maintain bth extens period bth extens period experienc bth wk events|pt event free event infect free event unrel elev free report arme-r armstudi arme-r arm apelli inc
strength soliri ultomiri could pose challeng
uptak pnh market
see signific unmet need pnh despit avail soliri ultomiri
outcom soliri treatment
yet defin true unmet need clinic perspect appear somewhat elus
 differ group confirm opson split fragment common event pnh patient eculizumab
clinic relev univers acknowledg expert risitano et al front immunol
 clear posit impact eculizumab surviv larg due prevent thromboembol event
necessarili mechanist associ hematolog respons risitano et al front immunol
 there paper point talk maximum reticulocytosi long-term ramif evercor isi
meanwhil soliri ultomiri maintain leadership pnh
 us germani japan soliri patient alreadi convert ultomiri
 guidanc convers us
 sale forc year experi employe sale market dec
potenti alxn-achn tie-up may present challeng
commerci outlook pnh
danicopan oral drug complement alxn pnh franchis
 like complement factor cfd inhibitor seek address extravascular hemolysi
 although market entri like later combin oral cfd inhibitor ultomiri
may pose strong competit forc pnh
 alxn experienc salesforc also tough hill climb
 add-on soliri
patient exclud religi reason
 hemoglobin hb increas g/dl week
 improv includ bilirubin ldh
facit-fatigu scale
earli promis data nv also intensifi competit pnh
complement factor inhibitor anoth potenti oral option pnh
 per nv phase trial initi possibl
 oral dose bid better danicopan potenti similar
add-on eculizumab
earli data support clinic util pnh
benefit rapid robust
lactat dehydrogenas ldh
normal week
benefit durabl
signific reduct
transfus patient
requir
 unit decreas
year prior studi
reduc
patient qualiti life qol
safe well-
 signific infect
earli data de-risk on-going phase pegasu trial data expect
head-to-head studi soliri
 ad top soliri initi random soliri monotherapi
suffici power show superior soliri
 power show g/dl hb week g/dl improv would home run
base earli studi think investor larg expect posit outcom pegasu
 due pick-up enrol later stage pegasu top-lin data expect januari
competit landscap emerg candid horizon rais
question pnh market opportun
phase asset
phase pegasu link data may support regulatori file pnh
 receiv orphan drug design pnh fda april
phase princ studi treatment-nav pnh patient on-going expand label snda
common mechan target difficult differenti soliris/ultomiri
timing-wis could next pnh agent challeng
base preval autoimmun hemolyt anemia aiha estim
 aiha patient ww cold agglutinin diseas cad cad
repres smaller portion estim us eu
respect met regul fall updat futur plan time
 rituximab soc cad unmet need remain high even rituximab treatment failur
rate high cad base literatur medacorp check model
cad patient receiv rituximab treatment fail/relaps need newer
 peak penetr us eu respect annual price
us eu per patient model gross sale ww
assumpt may conserv howev posit phase cardin data sutimlimab
sni nr may mean second-to-market statu like pnh see tough
competit ahead given sni establish presenc hematolog space
zanella barcellini haematologica orpha net visibl alpha svb leerink research
autoimmun hemolyt anemia aiha background
includ cold agglutinin diseas cad warm aiha waiha
agglutinin ca invari igm bind erythrocyt
hemolysi caus gener classic pathway
mechan
altern lectin classic pathway converg
upstream target soliris/ultomiri op
standard
rituximab soc cad case report suggest combin option
overal respons disease-fre surviv year
earli promis data phase plaudit studi
regulatori strategi updat earli
berentsen et al blood go rs et al blood zanella barcellini haematologica compani present svb leerink research
less warm role complement aiha
role complement warm aiha
 erythrocyt coat warm-react auto-ab igg
phagocytos macrophag spleen
activ classic complement pathway
phagocytos reticulo-endotheli cell liver
 intravascular hemolysi involv
complex usual promin
 complement-medi cell lysi hardli essenti
hemolysi patient
stronger implic complement cad
 agglutinin ca auto-ab bind erythrocyt igm
bind ca
 igm activ classic pathway complement
 coat erythrocyt phagocytos liver may
activ termin complement low
soliri shown benefit extravascular
hemolysi main mechan
exist option treat warm aiha
 gener steroid use
splenectomi rituximab
immunosuppress see
over-transfus speed
treatment option also lack cad
 immunosuppress drug
benefit inconsist efficaci
particularli termin
berentsen hematol zanella barcellini haematologica svb leerink research
consist underli biolog demonstr
benefit also durabl cad patient
address intra-
normal near normal
improv time suggest
therapeut valu cad
improv potenti util also observ waiha
patient albeit subset patient
address intra-
normal near normal
importantli
 report waiha
almost normal cad patient waiha program de-emphasize
normal ldh near-norm hb
 cad patient closer normal
benefit rel weaker
 despit increas hb seem
lower cad g/dl
occasion spike seen ldh
 magnitud outcom benefit
cad patient
base data hand
 cad studi updat earli
 re-evalu opportun
clinic
phase studi sutimlimab shown robust improv
 inhibit part complex upstream classic complement cascad lectin
 improv observ hemoglobin transfus independ treatment
north acquir bivv up-front mileston
 expedit develop breakthrough therapi design btd fda orphan drug
design fda/ema
 soliri preced success cad may open complement-medi diseas
 deal also includ follow-on mab sq administr less frequent dose
bivv acquir sni nr acquisit announc complet march
sutimlimab show efficaci phase cardin
sutimlimab alreadi demonstr posit efficaci phase trial cardin
 pivot open-label single-arm studi adult primari cad recent blood transfus
 dose fix weight-bas via iv day eow thereaft week
 primari composit endpoint increas hb g/dl baselin hb g/dl end
absenc transfus week
posit result announc american societi hematolog
hb g/dl increas g/dl
remain transfusion-fre week
 total bilirubin facit-fatigu score also improv
 regulatori bla approv
 primari endpoint increas hb g/dl baselin absenc transfus
week
acquisit bring heavyweight cad/aiha competit landscap
sni bivv/tru north lb gorilla cad competit landscap
 sni ahead timelin could first market cad
 back resource-heavi sni could mean signific competit later entrant
sni employe sale forc function
data expect
 present phase plaudit data european hematolog associ eha
 sni announc phase cardin data cadenza remain on-going
base estim preval glomerulopathi believ
 patient us eu respect like mani rare diseas
like remain under-diagnos despit high morbid like progress end stage
renal diseas esrd requir dialysi kidney transplant
 high competit small market prior decis pursu awar
agent space achn avacopan nv
 peak penetr us eu respect annual
price us eu per patient model peak gross sale
ww posit trend observ phase discoveri trial encourag
therefor assign probabl success po us eu approv peak
penetr assumpt us eu reach
glomerulopathi background
character promin glomerular deposit
scant immunoglobulin presenc kidney glomeruli
previous classifi either dens deposit diseas
mechan
altern lectin classic pathway converg
standard
preval us eu
incid us eu new case per year
soc blood pressur control immunosuppress
anecdot report soliri eculizumab show efficaci
phase discoveri data time point
overact complement deposit damag
believ trigger overact altern pathway
 exact caus remain unknown could genet acquir
patient estim affect across us japan
 patient progress kidney failur year
 patient kidney transplant experi recurr diseas
phase discoveri data proof-of-concept shown
earli proof-of-concept data
 treat patient show decreas upcr baselin
egfr stabl day particularli patient low egfr baselin
effect biomark serum plasma support moa
 small sampl size promis
patient exclud analysi due non-compliance
egfr calcul chronic kidney diseas epidemiolog collabor
 treatment-emerg advers event teae seriou studi discontinu due
 event mostli mild moder
howev contrari initi plan scope appear
narrow complement depend nephropathi
 asn kidney week data cover
 asid discoveri trial complet enrol across
intend advanc clinic develop
 develop path igan pend evalu subgroup patient
 de-priorit primari membran nephropathi ln
competit brew pend clinic data stand
given implic investig agent target complement system
cumbersom competitor oral administr disadvantag pend data
trial vy rare diseas popul sponsor face enrol challeng
sq-deliveri may hinder effort latter trial
 expert opin total number patient avail trial rate limit factor
trial seem current make slower progress toward ultim enrol goal earn
 site activ plan wrap enrol shortli februari enrol
patient object enrol two phase trial patient achn
 ultra-rar clinic trial typic basic end recruit one two patient per clinic trial enrol
drugmoasponsorphasecomplet date factor receptor antagonistregion factor cfd inhibitorachndrugrout apelli inc
base estim preval geograph atrophi ga believ
 ga patient us eu ga late stage age-rel macular
degener chronic diseas retina lead caus visual disabl
elderli individu affect peopl ww lower patient qualiti life
 lack competit approv therapi render ga market ripe take
complement-target approach fail lampalizumab eculizumab rais doubt
complement therapeut target ga yet similar zimura inhibitor also
shown limit lesion growth phase studi
 peak penetr us eu respect ga annual price
us eu per patient model peak gross sale ww
slow lesion size seen phase filli may approv ascrib
probabl success po us eu approv peak penetr us
eu reach
geograph atrophi ga background
nearli complet loss retin pigment epithelium rpe cell
drusen- neovascular-associ
precis mechan underli ga remain elucid
mechan
altern lectin classic pathway converg
complement protein cfi cfh etc implic ga
base genome-wid associ studi gwa
standard
preval million ww million us
chronic anti-vegf patient progress ga
inflamm visual cycl neuroprotect cell replac
promis data phase filli studi
initi phase derbi oak studi
temporarili paus inflamm patient studi
resum enrol complet expect
ga approv base meaning reduc lesion size
 chang squar root geograph atrophi ga lesion size baselin month
 number sever local system treatment emerg advers event teae
separ curv suggest monthli dose yield
 lesion size smaller
cohort compar sham
everi month eom
sham behav expect
second diseas progress resum catch-up apl-
 chang squar root geograph atrophi ga lesion size baselin month
 number sever local system treatment emerg advers event teae
diseas progress resum cohort still show statist
treatment may disease-modifi
 analysi six-month period suggest similar rate progress irrespect prior treatment
 sign catch-up diseas progress even off-treat
statist signific lesion size question
clinic meaning phase filli data
ga rapid extens deterior lead vision loss treatment goal
preserv vision
prevent convers dri age-rel macular degener wet
on- off-treat patient continu declin visual acuiti va
best treatment yield compar va sham worst va declin wors
medacorp kol believ ophthalmologist spoil robust efficaci seen anti-vegf
old demograph may lose motiv treatment letter declin year
new onset exud also yellow flag physician patient
exud dose-depend
 choroid neovascular cnv confirm case refer exud
develop exud associ substanti chang va
studi eye exud treatment patient discontinu studi treatment
 patient treat anti-vegf
rate give patient diseas didnt concern one medacorp kol
cautiou appeal util even avail today
 context patient kol treat annual ga patient
eomsham pooledal exud studi eye histori cnv fellow exud studi eye cnv histori fellow exud studi eye apelli inc
patient will trade ga onset exud vice versa
cnv exud
endophthalm culture-posit result coagulase-neg staphylococcu
regard incid endophthalm
 never event happen kol also believ risk lower phase
 kol consid seriou problem given higher incid anti-vegf
 iop increas bad said one kol
 howev context import magnitud increas whether clinic meaning
posit one kol point lack inflamm inject phase filli data
advers event eomsham pooledn subject studi pressur non-ocular relat ocular studi relat system non-ocular apelli inc
know know think address
market strike us home-run opportun
given patient old age risk-benefit profil like weigh heavili treatment decis
similar age enrol lampalizumab trial consist typic
split subtyp assumpt
among ga patient medacorp kol see non-subfov patient address
 extrafov atrophi locat away geometr center fovea
 juxtafov atrophi confin area geometr center fovea
 subfov atrophi directli beneath geometr center fovea
holz fg et al jama ophthalmol liao ds et al ophthalmolog sharma singerman lj retin physician svb leerink research
base phase filli outcom phase derbi oak studi
way could lead regulatori file ga
 trial list clinicaltri gov link link
 primari endpoint chang total area ga lesion base fundu autofluoresc
 importantli chang inclusion/exclus criteria phase filli studi
 best correct visual acuiti bcva letter etdr snellen equival
 ga lesion size one lesion multifoc
 neovascular fellow eye exclusionari
 power power show filly-lik result
despit earli observ inflamm new batch quick
workaround result studi resumpt
shortli phase studi commenc septemb voluntarili paus dose
chang formul lyophil phase vs trehalos formul phase
 reconstitut lyophil hour commerci attract trehalos alreadi use lucenti
announc resumpt phase studi march ahead prior guidanc
 current suppliers/manufactur materi
 new product test on-going phase trial particip
 manufactur suffici suppli new conduct entir phase program
 derbi oak studi enrol complet anticip line origin guidanc
evolut approv endpoint ga suggest regulatori
approv possibl help phase filli data
dark adapt microperimetri visual function questionnair advanc
potenti endpoint clinic trial
 ga progress highli variabl individu associ visual acuiti va also poor
 autom measur prefer higher precision/accuraci detect chang
significantli greater devic margin error
outset nei/fda symposium discuss clinic endpoint ga includ
 anatom progress ga fda would requir differ time point primari endpoint
 visual acuiti va ideal sinc morpholog chang occur slowli
updat view potenti endpoint metric nei/fda symposium includ
 fda prefer function anatom endpoint visual field contrast sensit light
sensit measur mention
 fda will consid anatom endpoint given variabl function endpoint
 altern develop sever scale composit endpoint wherein prevent
format exud neovascular prevent convers drusen nascent ga
ga arrest growth drusen drusen-onli eye evalu
although definit complement protein may contribut
pathogenesi ga
interestingli human donor eye possess drusen phenotyp show complement
associ termin complement complex red bruch
membran bm rpe cell pigment also shown green
ab green observ
drusen rpe background yellow
complement protein express retina retin pigment epithelium rpe rpe/choroid r/ch complement
protein natur express liver
genome-wid associ studi gwa implic complement gene
pathogenesi cfh promin
 model increas risk ga cfh variant decreas risk variant
 associ found progress ga variant cfh
despit associ complement protein role pathogenesi remain unclear
 lack reliabl anim model setback
 associ data inform fall short establish causal role complement
complement system believ role age-rel macular
gener model aris notion
dysfunct rpe cell
 local system may due
inappropri immun activ
stimul cytokin degener rpe
cell exacerb damag
pan-immunosuppress may double-
potent select complement inhibit
prior failur complement inhibit add
risk ga
prior filli result rhhbi mahalo data support
target complement ga
effect size widen cfi patient
identifi patient potenti amen treatment cfi
 slower monthli lampalizumab arm benefit less frequent dose eom
 separ curv seen earli month maintain
 lesion growth rapid complement factor risk-allel carrier cfi lampalizumab
efficaci sub-popul
proof concept establish favor safeti warrant continu develop
 proof mechan suppress cfd rapid clearanc half-lif hour establish
 alarm safeti signal ocular believ associ intravitr administr
surpris phase chroma spectri data rais caution
mechan
larger phase studi chroma spectri
fail replic prior trial success
 baselin featur similar phase mahalo
 pool patient data show treatment benefit
 meaning differ cfi cfi- sub-group
inhibit altern pathway ap
 correl causat caution warrant
interpret complement protein link
 danger signal earlier smaller trial
light result chroma
spectri one may hypothes may
relat small sampl size
may occur chanc
chroma spectri pool
meaning differ across arm
remain unclear whether complement
cascad appropri intraocular
therapeut target ga least
altern pathway via complement factor
downstream cascad via
lampalizumab setback open competit landscap
implic complement-target drug remain seen
lampalizumab rhhbi failur open door other
 phase spectri top line septemb chroma top line novemb fail
 trial ident design double-mask random global studi evalu mg
administ intravitr ivt
complement-target mechan pursu on-going clinic trial
 like lampalizumab zimura target variou compon complement
 pend posit data could first approv drug ga
 phase trial zimura show reduct lesion growth compar sham control
zimura data suggest potenti slow loss visual acuiti va
 unclear mechan behind rhhbi boehring
drugmoasponsorphasecomplet date estimate march format toxic vitamin energi reduc oligo silenc factor replacementlineag cell complement modulatorgyroscop apelli inc
iv background
compstatin
util own right deriv compstatin known
expect broaden market potenti
compound pipe nebul inject sq ivt
cyclic peptid right obtain gener dr john lambri upenn
 benefit peptid vs small molecul high select low toxic
long-act modifi form short-act via linker
zanella barcellini haematologica svb leerink research
mechan action steric inhibit complement
bound compstatin interfer interact prevent cleavag product
form
 believ reduct could yield better prognosi inhibit
bind pocket compstatin lie domain toward c-terminu
 bound compstatin believ steric hinder bind
unlik compstatin undergo drastic conform chang
test abl show
 specif potent origin compstatin
 potent inhibit classic altern pathway
zanella barcellini haematologica svb leerink research
risk-shar collabor add non-dilut financ leverag
oper clinic expertis
term deal
 tie specif pre-defin clinic mileston expect
 tie specif pre-defin clinic mileston
 also enter agreement tie cad/waiha develop
registr process
behind next-gen contempl adjunct
therapi address complic gene therapi
target complement level enhanc gene therapi approach
 rational program
increas effici gene therapi deliveri protect aav
minim format anti-aav neutral antibodi nab
prevent unwant inflammatori reaction aav lead organ damag
 healthi volunt rang dose test mg mg
 complement activ control within hour administr last hour
 shorter intraven iv administ
opportun current includ valuat
patent protect
 class compound gener cover specif recit activ compon
 compstatin analog prolong vivo includ and/or method treatment
dose regimen treat particular complement-depend diseas
 dose dose regimen intravitr ivt subcutan sq administ
 method treat eye disord associ complement activ potentia acquisit
 expir
manag combin expertis scienc industri
cedric francoi ph co-found presid ceo
co-found potentia pharmaceut
member research team perform first success hand transplant
univers leuven ph physiolog univers louisvil
pascal deschatelet ph co-found
co-found potentia pharmaceut
co-found syntetica fine chemic
ph organ chemistri
clinic research director
univers cordoba ph physiolog univers louisvil
manag director head life scienc invest bank rb citizen
mba columbia busi school biolog harvard univers
svp corpor develop svp global market commerci strategi
head commerci eusa pharma
european market team head uk market
 sc hon medic biochemistri univers london
david watson jd gener counsel vice-president corpor develop
member frost brown todd llc
 vanderbilt law school harvard colleg
ultomiri approv like lower price threshold pnh
base ultomiri wac price per mg ml volum
total incom expens
chang cash
loss asset dispos
proce common stock
proce convert note/debt
proce warrant
discount rate/cost equiti
complement-respons aav gene therapi
